Head to Head Study Epi proColon and FIT
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01580540 |
Recruitment Status :
Completed
First Posted : April 19, 2012
Last Update Posted : August 4, 2015
|
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date | April 17, 2012 | ||||||
First Posted Date | April 19, 2012 | ||||||
Last Update Posted Date | August 4, 2015 | ||||||
Study Start Date | March 2012 | ||||||
Actual Primary Completion Date | November 2012 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures |
Non-inferiority of Epi proColon test result compared to FIT result using a 95% confidence interval for difference in sensitivities and differences in specificities below a strictly defined margin. [ Time Frame: At completion of testing. ] | ||||||
Original Primary Outcome Measures | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures | Not Provided | ||||||
Original Secondary Outcome Measures | Not Provided | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title | Head to Head Study Epi proColon and FIT | ||||||
Official Title | Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population | ||||||
Brief Summary | The study aims to show non-inferiority in the clinical performance of the investigational assay, Epi proColon, to FIT using matched blood and stool specimens from screening-guideline eligible subjects. | ||||||
Detailed Description | There is strong evidence supporting the use of FOBT in CRC screening, with the earliest randomized controlled trials demonstrating a reduction in CRC incidence and mortality from CRC screening. Despite the implementation and incremental improvements in gFOBT- and FIT-based tests, they continue to represent a small percentage of CRC screening and currently remain largely the province of large, integrated healthcare delivery systems. Reasons for the limited adoption of stool-based testing are complicated, but include lack of physician recommendation, patient preferences, and cultural barriers. Availability of a blood-based test may overcome the adoption challenges presently facing stool-based CRC screening and facilitate better compliance with CRC screening guidelines. However, there are currently no FDA-approved in vitro diagnostic tests for detection of CRC in a blood sample. As such, a high through-put blood-based test with performance characteristics similar to fecal testing could satisfy this clinical need. This study is designed to prospectively collect matched blood and stool specimens and clinical data from screening guideline-eligible subjects found to have invasive colorectal cancer (CRC) at colonoscopy, i.e. AJCC/UICC stages I, II, III, and IV, with collection of specimens and testing after colonoscopy and from screening guideline-eligible subjects with blood and stool specimens collected before colonoscopy. A completed subject will have a FIT result, an Epi proColon result, and a medical diagnosis/colonoscopy determined clinical status (CRC, non-CRC). Demographic and baseline covariates will be reported for each individual. |
||||||
Study Type | Observational | ||||||
Study Design | Observational Model: Case-Control | ||||||
Target Follow-Up Duration | Not Provided | ||||||
Biospecimen | Retention: Samples With DNA Description: Plasma
|
||||||
Sampling Method | Non-Probability Sample | ||||||
Study Population | Subjects are recruited from gastroenterology clinics and surgical centers in the United States. | ||||||
Condition | Colorectal Cancer | ||||||
Intervention | Not Provided | ||||||
Study Groups/Cohorts |
|
||||||
Publications * | Johnson DA, Barclay RL, Mergener K, Weiss G, König T, Beck J, Potter NT. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS One. 2014 Jun 5;9(6):e98238. doi: 10.1371/journal.pone.0098238. eCollection 2014. | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status | Completed | ||||||
Actual Enrollment |
336 | ||||||
Original Estimated Enrollment |
300 | ||||||
Actual Study Completion Date | November 2012 | ||||||
Actual Primary Completion Date | November 2012 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria | Inclusion Criteria: Group A
Group B
Exclusion Criteria: Group A
Group A and B
|
||||||
Sex/Gender |
|
||||||
Ages | 50 Years to 84 Years (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers | Yes | ||||||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries | Puerto Rico, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number | NCT01580540 | ||||||
Other Study ID Numbers | Epigenomics-SPR 0022 | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product | Not Provided | ||||||
IPD Sharing Statement | Not Provided | ||||||
Current Responsible Party | Epigenomics, Inc | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor | Epigenomics, Inc | ||||||
Original Study Sponsor | Same as current | ||||||
Collaborators | Not Provided | ||||||
Investigators |
|
||||||
PRS Account | Epigenomics, Inc | ||||||
Verification Date | July 2014 |